Please assess the completion status of the following clinical trial:

Trial Title: Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
There are two categories of participants: Patients with Burkitt Lymphoma, Diffuse large B-cell lymphoma or retinoblastoma; and health providers at BMC who participate in testing and/or use of mNavigator. Eligibility criteria are as follows:~A) For patients:~\*All patients will be registered in the pre-diagnosis cohort but, for the purposes of this study, primary and secondary outcomes will only be tracked for patients with BL, DLBCL or RB once the diagnosis is made.~Inclusion Criteria:~* Inclusion criteria are pediatric oncology patients diagnosed with Burkitt Lymphoma, Diffuse large B-cell lymphoma or Retinoblastoma under the age of 18~Exclusion criteria:~* Patients older than 18 years at registration~* Patients with diagnoses other than Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.~B) For providers:~Inclusion Criteria:~* Must be health provider or staff working at BMC who provides care for cancer patients.~* Must be 18 years of age or older.~Exclusion:~- Persons younger than 18 years of age.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mNavigator (Type: EXPERIMENTAL): Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
- Historical controls (Type: NO_INTERVENTION): BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.

Based on this trial design, predict the completion outcome and termination type (if applicable).